Winter Park, Florida–(Newsfile Corp. – February 26, 2025) – ADIA Nutrition Inc. (OTC Pink: ADIA), a leader in innovative nutritional products and regenerative medical treatments, is excited to announce that it has successfully removed its shell risk designation from OTC Markets, a pivotal achievement on its accelerated journey to uplist from the OTC Pink Sheets to the OTCQB Venture Market. The company extends its heartfelt gratitude to OTC Markets for their collaboration and swift action in facilitating this milestone, reinforcing Adia Nutrition’s commitment to transparency, growth, and enhanced investor visibility.
To view an enhanced version of this graphic, please visit:
https://healthtechnologynet.com/wp-content/uploads/2025/02/242453_shell_risk_after_2_550.jpg
The removal of the shell risk designation was a critical requirement for achieving OTCQB status, underscoring Adia Nutrition’s operational integrity and dedication to meeting elevated market standards. The company has been working closely with OTC Markets to fulfill all uplisting criteria, including a comprehensive third-party audit, and thanks OTC Markets for their partnership in expediting the shell risk removal process. This rapid progress highlights Adia Nutrition’s proactive approach and sets the stage for an imminent uplisting.
“We’re thrilled to have the shell risk designation lifted so quickly, and we sincerely thank OTC Markets for working with us to make this happen on our accelerated path to the OTCQB,” said Larry Powalisz, CEO of Adia Nutrition. “With this hurdle cleared, I’m more confident in sharing exciting updates and information with our investors-details I wouldn’t have been able to disclose before. This milestone reflects our momentum, and it’s just the beginning of what’s to come.”
The OTCQB Venture Market offers greater transparency, liquidity, and investor trust, providing an ideal platform for Adia Nutrition to showcase its groundbreaking work in stem cell therapies and premium nutritional products to a wider audience. The swift removal of the shell risk designation demonstrates the company’s efficiency and determination, promising a wealth of exciting developments on the horizon.
Stay tuned for further updates as Adia Nutrition continues to push boundaries in the industry. For more information about the company’s progress or to explore its offerings, please contact at ceo@adiamed.com or 321-788-0850.
About ADIA Nutrition Inc.:
Adia Nutrition Inc. is a publicly traded company (OTC Pink: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments
Website: www.adianutrition.com
Website: www.adiamed.com
Website: www.adialabs.com
Website: www.biolete.com
Website: www.cementfactory.co
Twitter (X): @ADIA_Nutrition
Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company’s current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company’s business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/242453
Health Journey Addresses 'Best GLP-1 Supplement' Question with Akkermansia-Based Formula Analysis as Six-Month Costs Compare…
A Revolutionary ATCA/VME/VXI 3D-Flow Board: 512 Channels, >2,800 Programmable Operations—Scalable to >50,000 Operations on Each…
After President Trump's Marijuana Executive Order, Will the DEA Act-or Be Compelled by the Courts?"Despite…
Boards and executive buyers are raising the 2026 bar for all product and service rankings…
Boards and executive buyers are raising the 2026 bar for all product and service rankings…
Tampa based Celebrity Board-Certified Plastic Surgeon Dr. Meegan Gruber expands an interactive approach that allows…
